Investigation of autophagy targets in neurodegeneration - new collaboration

Alex Whitworth leads one of three academic teams in Cambridge involved in a new collaboration set up through the Milner Therapeutics Consortium.

Autophagy is a major protein and organelle recycling and degradation pathway and is an attractive therapeutic target against various human diseases. This collaboration will investigate autophagy targets in the context of neurodegeneration. The project involves John Skidmore's team at the ALBORADA Drug Discovery Institute and Nicholas Ktistakis' group at the Babraham Institute, along with three pharma companies - Astex, Eisai and Eli Lilly and Company.

Further details can be found in the Milner Therapeutics Institute's press release.

2 March 2021